CURANEX PHARMACEUTICALS INC Financials
This page shows CURANEX PHARMACEUTICALS INC (CURX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing rather than revenue funds this business, with a research-heavy cost base driving cash use and balance-sheet expansion.
Between FY2024 and FY2025, net loss worsened sharply, yet ROA and ROE became less negative because financing enlarged the asset and equity base faster than losses consumed it. That is why a business with no reported revenue can look less weak on percentage returns even while its cash demands intensify.
Cash conversion is the key operating clue: FY2025 operating cash outflow of
Spending mix also shows what management is paying for:
Financial Health Signals
CURANEX PHARMACEUTICALS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
CURANEX PHARMACEUTICALS INC passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
CURANEX PHARMACEUTICALS INC reported a net loss of $4.2M while operations used $10.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
CURANEX PHARMACEUTICALS INC reported an operating loss of $4.2M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
CURANEX PHARMACEUTICALS INC reported -$4.2M in net income in fiscal year 2025. This represents a decrease of 1068.8% from the prior year.
CURANEX PHARMACEUTICALS INC earned -$0.17 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
CURANEX PHARMACEUTICALS INC held $5.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
CURANEX PHARMACEUTICALS INC's ROE was -37.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 34.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
CURANEX PHARMACEUTICALS INC invested $3.0M in research and development in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
CURX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 |
|---|---|---|---|
| R&D Expenses | N/A | $3.0M | N/A |
| SG&A Expenses | N/A | $1.3M+331.6% | $290K |
| Operating Income | N/A | -$4.2M-1061.2% | -$365K |
| Interest Expense | N/A | $9K | N/A |
| Net Income | N/A | -$4.2M-1068.8% | -$362K |
| EPS (Diluted) | — | -$0.17 | -$0.03 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CURX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 |
|---|---|---|
| Total Assets | $11.6M+2135.8% | $518K |
| Current Assets | $11.2M+2067.7% | $518K |
| Cash & Equivalents | $5.0M+3258.2% | $149K |
| Total Liabilities | $361K+2377.1% | $15K |
| Current Liabilities | $137K+840.2% | $15K |
| Total Equity | $11.2M+2128.8% | $503K |
| Retained Earnings | -$4.8M-678.8% | -$622K |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
CURX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 |
|---|---|---|---|
| Operating Cash Flow | -$12.1M | -$10.5M-1787.1% | -$556K |
| Financing Cash Flow | N/A | $15.3M+2329.6% | $630K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CURX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 |
|---|---|---|
| Return on Equity | -37.7%+34.2pp | -71.8% |
| Return on Assets | -36.5%+33.3pp | -69.8% |
| Current Ratio | 81.93+46.4x | 35.54 |
| Debt-to-Equity | 0.030.0x | 0.03 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where CURANEX PHARMACEUTICALS INC Ranks
Frequently Asked Questions
Is CURANEX PHARMACEUTICALS INC profitable?
No, CURANEX PHARMACEUTICALS INC (CURX) reported a net income of -$4.2M in fiscal year 2025.
What is CURANEX PHARMACEUTICALS INC's return on equity (ROE)?
CURANEX PHARMACEUTICALS INC (CURX) has a return on equity of -37.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is CURANEX PHARMACEUTICALS INC's operating cash flow?
CURANEX PHARMACEUTICALS INC (CURX) recorded an outflow of $10.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are CURANEX PHARMACEUTICALS INC's total assets?
CURANEX PHARMACEUTICALS INC (CURX) had $11.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does CURANEX PHARMACEUTICALS INC spend on research and development?
CURANEX PHARMACEUTICALS INC (CURX) invested $3.0M in research and development during fiscal year 2025.
What is CURANEX PHARMACEUTICALS INC's current ratio?
CURANEX PHARMACEUTICALS INC (CURX) had a current ratio of 81.93 as of fiscal year 2025, which is generally considered healthy.
What is CURANEX PHARMACEUTICALS INC's debt-to-equity ratio?
CURANEX PHARMACEUTICALS INC (CURX) had a debt-to-equity ratio of 0.03 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is CURANEX PHARMACEUTICALS INC's return on assets (ROA)?
CURANEX PHARMACEUTICALS INC (CURX) had a return on assets of -36.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is CURANEX PHARMACEUTICALS INC's cash runway?
Based on fiscal year 2025 data, CURANEX PHARMACEUTICALS INC (CURX) had $5.0M in cash against an annual operating cash burn of $10.5M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is CURANEX PHARMACEUTICALS INC's Piotroski F-Score?
CURANEX PHARMACEUTICALS INC (CURX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CURANEX PHARMACEUTICALS INC's earnings high quality?
CURANEX PHARMACEUTICALS INC (CURX) reported a net loss of $4.2M while operations used $10.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can CURANEX PHARMACEUTICALS INC cover its interest payments?
CURANEX PHARMACEUTICALS INC (CURX) reported an operating loss of $4.2M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.